Structure Search

```
=> FILE CAPLUS
FILE 'CAPLUS' ENTERED AT 16:47:43 ON 15 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Feb 2007  VOL 146 ISS 8
FILE LAST UPDATED: 14 Feb 2007  (20070214/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> D QUE L13
L2                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26
```

```
STEREO ATTRIBUTES: NONE
L4             45 SEA FILE=REGISTRY FAM FUL L2
L7             62 SEA FILE=CAPLUS ABB=ON  PLU=ON  L4(L)PREP+NT/RL
L8             52 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 AND PATENT/DT
L9             44 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8 AND (PRY>=2001 OR PY>=2001
                  OR AY>=2001)
L11            10 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 NOT L8
L12             4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 AND PY>=2001
L13            48 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 OR L12


=> D IBIB ED ABS 1-48

L13  ANSWER 1 OF 48  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1339720  CAPLUS  Full-text
DOCUMENT NUMBER:          146:82189
TITLE:                    Preparation of L-threonine derivatives with high
                          therapeutic index
INVENTOR(S):              Chandran, V. Ravi
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 60pp., Cont.-in-part of U.S.
                          Ser. No. 343,557.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------------      ----   --------    ---------------------    --------
     US 2006287244          A1    20061221    US 2006-442027           20060526 <--
     WO 2005046575          A2    20050526    WO 2004-US24901          20040729 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     US 2006241017          A1    20061026    US 2006-343557           20060130 <--
PRIORITY APPLN. INFO.:                        US 2003-491331P     P    20030729 <--
                                              WO 2004-US24901     A2   20040729 <--
                                              US 2006-343557      A2   20060130 <--

ED   Entered STN:  22 Dec 2006
AB   The invention is directed to novel therapeutic compds. comprised of an L-
     threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or
     acylating function.  These high-therapeutic index derivs. have the same
     utility as the drug from which they are made and they have enhanced pharmacol.
     and pharmaceutical properties, with the addnl. advantage of separating various
     enantiomeric and diastereomeric drugs into their individual isomers.  The
     examples describe the synthesis and activities of L-threonine derivs. of (±)-
     and (+)-(S)-ibuprofen, (±)- and (+)-(S)-ketoprofen, (-)-(S)-ketorolac,
     aspirin, and fenofibric acid.  The synthesis and activity of several L-serine
     and L-hydroxyproline analogs were also described.  Thus, the hydrochloride of
     (+)-(S)-ibuprofen ester of L-threonine was prepared, and its free base
```

examined for analgesic, gastric mucosal irritation, toxicity, and pharmacokinetic properties.

L13 ANSWER 2 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1339495 CAPLUS Full-text
DOCUMENT NUMBER: 146:68762
TITLE: Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
INVENTOR(S): Law, Devalina; Henry, Rodger F.; Lou, Xiaochun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of U.S. Ser. No. 72,568.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006287289	A1	20061221	US 2005-177640	20050708 <--
US 2005209211	A1	20050922	US 2005-72568	20050303 <--
CA 2558629	A1	20050929	CA 2005-2558629	20050307 <--
EP 1745053	A1	20070124	EP 2005-724824	20050307 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006211676	A1	20060921	US 2005-221427	20050908 <--
WO 2007008672	A1	20070118	WO 2006-US26536	20060710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:			
US 2004-553643P	P	20040316 <--	
US 2005-72568	A2	20050303 <--	
WO 2005-US7359	W	20050307 <--	
US 2005-177640	A2	20050708 <--	
US 2005-221427	A	20050908 <--	

ED Entered STN: 22 Dec 2006
AB A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compns. comprising them and made with them, and methods of treatment using them are disclosed. Thus, a crystalline cefdinir trihemihydrate (preparation given) was heated at 75 °C for 30 min to give crystalline cefdinir sesquihydrate.

L13 ANSWER 3 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1338411 CAPLUS Full-text
DOCUMENT NUMBER: 146:62516
TITLE: Cefdinir process
INVENTOR(S): Reddy, Bandi Parthasaradhi; Reddy, Kura Rathnakar; Reddy, Rapolu Raji; Reddy, Dasari Muralidhara; Murali,

Nagabelli
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 10pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006134607	A1	20061221	WO 2005-IN199	20050615 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2005-IN199 20050615 <--
ED Entered STN: 22 Dec 2006
GI



I

AB This invention provides an improved process for the preparation of high assayed cefdinir (I). Thus, crude cefdinir is added to water at 25-30° and then 18% hydrochloric acid is slowly added to form a clear solution The solution is cooled to -5° and stirred for 5 min at -5° to +5°. Then temperature of the mass is raised to 35-38°C, stirred for 15 min at the same temperature To the reaction mass carbon is added at 35-38° and stirred for 30 min at 35-38°. Then the contents are filtered on hiflo bed and washed with water. The filtrate is then cooled to 25°, the pH is slowly adjusted to 2.6 with saturated sodium bicarbonate solution and stirred for 60 min at 25-30°. Filtered the solid, washed with water and dried at 40° under vacuum to give high assayed cefdinir.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1173157 CAPLUS Full-text
DOCUMENT NUMBER: 145:454873
TITLE: A novel crystalline form of cefdinir
INVENTOR(S): Reddy, Bandi Parthasaradhi; Reddy, Kura Rathnakar;

Reddy, Rapolu Raji; Reddy, Dasari Muralidhara; Murali, Nagabelli
PATENT ASSIGNEE(S): Hetero Drugs Limited, India
SOURCE: PCT Int. Appl., 18pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117794	A1	20061109	WO 2005-IN135	20050502 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2005-IN135 20050502 <--
ED Entered STN: 09 Nov 2006
GI



I

AB This invention relates to a novel crystalline form of cefdinir (I), process for its preparation and to a pharmaceutical compns. containing it. Thus, cefdinir is added to water at 20-25° and then hydrochloric acid (18%) is added at 20-25° to get a clear solution To the solution activated carbon is added at 20-25°, stirred for 30 min, filtered through hyflo bed and washed with water. Then the pH of the filtrate is adjusted to 6.5 with saturated bicarbonate solution at 5-8°, stirred for clear solution, activated carbon is added and stirred for 30 min at 5-8°. The reaction mass is filtered through hyflo bed, washed with water, 1:1 sulfuric acid is dumped to the above solution at 5-8° (pH 2.8) and then stirred for 60 min at 3-5°. The resulting solid is filtered, washed with water and dried at 40° under vacuum to give cefdinir form H.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1091819 CAPLUS Full-text
TITLE: Synthesis of potential related compounds of Cefdinir

AUTHOR(S): Rao, Korrapti V. V.; Dandala, Ramesh; Rani, Ananta; Naidu, Andra
CORPORATE SOURCE: Chemical Research Department, APL Research Center, Hyderabad, 500 072, India
SOURCE: ARKIVOC (Gainesville, FL, United States) (2006), (15), 22-27
CODEN: AGFUAR
URL: http://www.arkat-usa.org/ARKIVOC/JOURNAL CONTENT/manuscripts/2006/06-2133CP%20as%20published%20mainmanuscript.pdf
PUBLISHER: Arkat USA Inc.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
ED Entered STN: 19 Oct 2006
AB The synthesis of three contaminants of Cefdinir, formed during the preparation of Cefdinir bulk drug, is described. The products identified as (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-8-oxo-3- vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid-5-oxide, (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-8-oxo-3- vinyl-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylicacid, and (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-8-oxo-3- methyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:979673 CAPLUS Full-text
DOCUMENT NUMBER: 145:342497
TITLE: Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
INVENTOR(S): Law, Devalina; Henry, Rodger F.; Lou, Xiaochun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of U.S. Ser. No. 177,640.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006211676	A1	20060921	US 2005-221427	20050908 <--
US 2005209211	A1	20050922	US 2005-72568	20050303 <--
CA 2558629	A1	20050929	CA 2005-2558629	20050307 <--
EP 1745053	A1	20070124	EP 2005-724824	20050307 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006287289	A1	20061221	US 2005-177640	20050708 <--
WO 2007008672	A1	20070118	WO 2006-US26536	20060710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 2004-553643P	P	20040316 <--
	US 2005-72568	A2	20050303 <--
	US 2005-177640	A2	20050708 <--
	WO 2005-US7359	W	20050307 <--
	US 2005-221427	A	20050908 <--

ED Entered STN: 21 Sep 2006

AB A novel crystalline cefdinir anhydrate and hydrates and ways to make them and use them are presented. Compns. comprising crystalline cefdinir anhydrate or hydrates and methods of using them in treatment of bacterial infection in a mammal, particularly in humans are also described. Thus, a crystalline cefdinir trihemihydrate (preparation given) was heated at 75° for 30 min to give crystalline cefdinir sesquihydrate.

L13 ANSWER 7 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2006:636734 CAPLUS Full-text
DOCUMENT NUMBER:	145:83172
TITLE:	Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
INVENTOR(S):	Law, Devalina; Henry, Rodger F.; Lou, Xiaochun
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S. Ser. No. 177,202. CODEN: USXXCO
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142563	A1	20060629	US 2005-222299	20050908 <--
US 2005209211	A1	20050922	US 2005-72568	20050303 <--
CA 2558629	A1	20050929	CA 2005-2558629	20050307 <--
EP 1745053	A1	20070124	EP 2005-724824	20050307 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006025399	A1	20060202	US 2005-177202	20050708 <--
WO 2007008674	A1	20070118	WO 2006-US26538	20060710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:	US 2004-553643P	P	20040316 <--
	US 2005-72568	A2	20050303 <--
	US 2005-177202	A2	20050708 <--
	WO 2005-US7359	W	20050307 <--
	US 2005-222299	A	20050908 <--

ED Entered STN: 30 Jun 2006

GI



I

AB A novel crystalline cefdinir anhydrate (I) and novel crystalline cefdinir hydrates, ways to make them and use them, compns. comprising them and made with them, and methods of treatment of bacterial infection using them were disclosed.

L13 ANSWER 8 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:636733 CAPLUS Full-text
DOCUMENT NUMBER: 145:90056
TITLE: Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
INVENTOR(S): Law, Devalina; Henry, Rodger F.; Lou, Xiaochun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 177,173.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142261	A1	20060629	US 2005-222313	20050908 <--
US 2005209211	A1	20050922	US 2005-72568	20050303 <--
CA 2558629	A1	20050929	CA 2005-2558629	20050307 <--
EP 1745053	A1	20070124	EP 2005-724824	20050307 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
WO 2007008673	A2	20070118	WO 2006-US26537	20060710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:		
US 2004-553643P	P	20040316 <--
US 2005-72568	A2	20050303 <--

US 2005-177173	B2	20050708 <--
WO 2005-US7359	W	20050307 <--
US 2005-222313	A	20050908 <--

ED Entered STN: 30 Jun 2006

AB A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compns. comprising them and made with them, and methods of treatment using them are disclosed.

L13 ANSWER 9 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:544796 CAPLUS Full-text
DOCUMENT NUMBER: 145:34227
TITLE: Crystalline cefdinir
INVENTOR(S): Daemon, Otto; Hartmann, Klaus; Raneburger, Johannes
PATENT ASSIGNEE(S): Austria
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006122165	A1	20060608	US 2005-294116	20051205 <--
GB 2421024	A	20060614	GB 2004-26837	20041207 <--

PRIORITY APPLN. INFO.: GB 2004-26837 A 20041207 <--

ED Entered STN: 09 Jun 2006

AB The present invention relates to a new crystalline form of cefdinir and processes for the preparation thereof. Furthermore, the present invention relates to pharmaceutical compns. comprising said new crystalline form of cefdinir and to processes for preparing these compns.

L13 ANSWER 10 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:495880 CAPLUS Full-text
DOCUMENT NUMBER: 144:495395
TITLE: Crystalline from of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir
INVENTOR(S): Pozzi, Giovanni; Ghetti, Paolo; Balsamo, Gaetano; Alpegiani, Marco; Cabri, Walter
PATENT ASSIGNEE(S): Antibioticos S.p.A., Italy
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006053625	A1	20060526	WO 2005-EP11385	20051024 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IT 2004-MI2231 A 20041119 <--
ED Entered STN: 26 May 2006
AB The invention relates to a crystalline Cefdinir ammonium salt having a diffraction spectrum specified in the claims.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:317409 CAPLUS Full-text
DOCUMENT NUMBER: 144:357655
TITLE: Crystalline forms of cefdinir potassium
INVENTOR(S): Maheshwari, Nitin; Prasad, Ashok; Prasad, Mohan; Kumar, Yatendra
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006035291	A1	20060406	WO 2005-IB2858	20050927 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-DE1854 A 20040927 <--
ED Entered STN: 06 Apr 2006
AB The present invention relates to a novel crystalline potassium salt of cefdinir - cefdinir potassium tetrahydrate, processes for its preparation, pharmaceutical compns. including cefdinir potassium tetrahydrate, and methods of treating bacterial infections using cefdinir potassium tetrahydrate. In addition, the present invention also relates to a mixture of cefdinir potassium dihydrate and cefdinir potassium tetrahydrate, processes for its preparation, pharmaceutical compns. including the mixture, and methods of treating bacterial infections using mixts. of cefdinir potassium dihydrate and cefdinir potassium tetrahydrate. Further it also relates to processes for preparing pure cefdinir and cefdinir potassium dihydrate from cefdinir potassium tetrahydrate. Potassium acetate (70 g) was added to a suspension of cefdinir (200 g) in a mixture of water (1000 mL) and acetone (1000 mL) at 25-30°. The reaction mixture was stirred at this temperature for three hours. The reaction mixture was then cooled to 10° and stirred for about two hours. The crystals were filtered, washed with aqueous acetone followed by acetone. The product was then dried at 25-30° in a hot air oven to obtain 189 g of cefdinir potassium tetrahydrate, yield: 94.5%, water content: 14.58%, and HPLC purity: 99.5%.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:167401 CAPLUS Full-text
DOCUMENT NUMBER: 144:239873
TITLE: Crystalline forms of cefdinir
INVENTOR(S): Mahendru, Manu; Aryan, Ram Chander; Kumar, Satish; Pandya, Bhargav; Duggal, Sanjam; Gade, Sanjay; Kumar, Yatendra
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018807	A1	20060223	WO 2005-IB52691	20050815 <--
WO 2006018807	A8	20060810		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	IN 2004-DE1508	A	20040816 <--
	IN 2004-DE1646	A	20040831 <--
	IN 2005-DE434	A	20050228 <--

ED Entered STN: 23 Feb 2006

AB The invention relates to processes for the preparation of crystalline polymorphic forms of cefdinir. More particularly, it relates to the preparation of crystalline polymorphic forms of cefdinir designated as Forms B and C. The invention also relates to pharmaceutical compns. that include the polymorphic forms B and C, and the use of the compns. for treating bacterial infections.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:103545 CAPLUS Full-text
DOCUMENT NUMBER: 144:177431
TITLE: Preparation of crystalline anhydrous cefdinir and crystalline cefdinir hydrates and uses for treating bacterial infection
INVENTOR(S): Law, Devalina; Henry, Rodger F.; Lou, Xiaochun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont.-in-part of U.S. Ser. No. 72,568.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006025399	A1	20060202	US 2005-177202	20050708 <--
US 2005209211	A1	20050922	US 2005-72568	20050303 <--
CA 2558629	A1	20050929	CA 2005-2558629	20050307 <--
EP 1745053	A1	20070124	EP 2005-724824	20050307 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2006142563	A1	20060629	US 2005-222299	20050908 <--
WO 2007008674	A1	20070118	WO 2006-US26538	20060710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:	US 2004-553643P	P	20040316 <--
	US 2005-72568	A2	20050303 <--
	WO 2005-US7359	W	20050307 <--
	US 2005-177202	A2	20050708 <--
	US 2005-222299	A	20050908 <--

ED Entered STN: 03 Feb 2006

AB The present invention relates to a novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compns. comprising them and made with them, and methods of treating bacterial infection by using them.

L13 ANSWER 14 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:100935 CAPLUS Full-text
DOCUMENT NUMBER: 144:170819
TITLE: Cefdinir polymorphic forms, and imidazole salt
INVENTOR(S): Jaweed Mukarram, Siddiqui Mohammed; Khan, Rashid Abdul Rehman; Mane, Avinash Seshrao
PATENT ASSIGNEE(S): Wockhardt Limited, India
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010978	A1	20060202	WO 2004-IB2171	20040630 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS,
MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2004-IB2171 20040630 <--

ED Entered STN: 03 Feb 2006

GI



I

AB A new crystalline Cefdinir imidazole salt (I) and polymorphic forms C, D and an amorphous form of Cefdinir were disclosed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:79174 CAPLUS Full-text

DOCUMENT NUMBER: 144:170818

TITLE: Preparation of tertiary amine salts of 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)acetic acid as intermediates for cefdinir

INVENTOR(S): Kremminger, Peter; Silberberger, Herbert

PATENT ASSIGNEE(S): Sandoz AG, Switz.

SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006008160	A1	20060126	WO 2005-EP7958	20050721 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-16379 A 20040722 <--

OTHER SOURCE(S): CASREACT 144:170818; MARPAT 144:170818
ED Entered STN: 27 Jan 2006
GI



I

AB Crystalline tertiary amine salts of 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)acetic acid compds. of formula (I) (R1, R2, R3 = independently unsubstituted or substituted alkyl, cycloalkyl or aryl; R4 = acyl) are prepared These salts may be obtained in anhydrous form and are useful in a reaction step with an activating agent in order to produce cefdinir. Thus, 25.0 g syn-2-(2-aminothiazol-4-yl)-2- [[(methylcarbonyl)oxy]imino]acetic acid monohydrate (water content: 8.0%) was suspended in 20 mL acetone at ambient temperature and 5.2 mL tributylamine was added. The mixture was cooled to -10° and stirred at this temperature for 60 and filtered to give, after washing with a small portion of cold acetone and dried in vacuum to give, 32.7 g tributylammonium syn-2-(2-aminothiazol-4-yl)-2-[[(methylcarbonyl)oxy]imino]acetate (water content: 0.1%) (II). II was converted into syn-2-(2-aminothiazol-4-yl)-2-[[(methylcarbonyl)oxy]imino]acetic acid 2-benzothiazolyl thioester by treatment with bis(benzothiazol-2-yl) disulfide and then condensed with 7-amino-3-vinyl-cephem-4-carboxylic acid to give 7-[2-(2-aminothiazol-4- yl)-2-[[(methylcarbonyl)oxy]imino]acetamido]-3-vinylcephem-4-carboxylic acid phosphate which was converted into cefdinir by treatment with a mixture of concentrated H2SO4 in MeOH.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 16 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:76118 CAPLUS Full-text
DOCUMENT NUMBER: 144:170817
TITLE: Preparation of alkamide solvates of 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)acetic acid as intermediates for cefdinir
INVENTOR(S): Kremminger, Peter; Silberberger, Herbert
PATENT ASSIGNEE(S): Sandoz AG, Switz.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006008161	A1	20060126	WO 2005-EP7963	20050721 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: GB 2004-16380 A 20040722 <--
OTHER SOURCE(S): CASREACT 144:170817; MARPAT 144:170817
ED Entered STN: 27 Jan 2006
GI



I

AB Crystalline N,N-dimethylalkamide solvates of 2-(2-aminothiazole -4-yl)-2(acyloxyimino)acetic acid compds. of formula (I) [R1 = H, (un)substituted alkyl; R4 = acyl] are prepared These compds. may be prepared in an anhydrous form and are useful in a reaction step with an activating agent in order to produce cefdinir. Thus, 15.0 g syn-2-(2-aminothiazol-4- yl)-2-[[(methylcarbonyl)oxy]imino]acetic acid dihydrate (H2O content 13.5%) was dispensed into 54.0 mL N,N-dimethylacetamide at 50° and stirred for 90 min. The crystalline suspension was cooled to 0°, treated with 150 mL CH2Cl2 and the white crystals were filtered, washed three times, each with 30 mL CH2Cl2, and dried over night in vacuum at 30° to give 15,9 g syn-2-(2-aminothiazol-4-yl)-2- [[(methylcarbonyl)oxy]imino]acetic acid N,N-dimethylacetamide solvate (II) (water content 0.4 %). II was converted into syn-2-(2-aminothiazol-4-yl)- 2-[[(methylcarbonyl)oxy]imino]acetic acid benzothiazol-2-yl thioester by treatment with bis(benzothiazol-2-yl) disulfide followed by amidation with 7-amino-3-vinylcephem-4-carboxylic acid and acidification with phosphoric acid to give 7-[2-(2-aminothiazol-4-yl)-2-[[(methylcarbonyl)oxy]imino]acet amido]-3-vinylcephem-4-carboxylic acid phosphate (III). Cefdinir was obtained by treatment of III with a mixture of concentrated H2SO4 and MeOH.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:54564 CAPLUS Full-text
DOCUMENT NUMBER: 144:128794
TITLE: News salts in the preparation of cephalosporin antibiotics
INVENTOR(S): Senthilkumar, Udayampalayam Palanisamy; Lakshmipathi, Venu Sanjeevi; Andrew, Gnanaprakasam; Chandrasekaran, Ramasubbu; Nagender Rao, Dindigala; Om Reddy, Gaddam
PATENT ASSIGNEE(S): Orchid Chemicals & Pharmaceuticals Limited, India
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006006040	A2	20060119	WO 2005-IB1888	20050704 <--
WO 2006006040	A3	20060921		
WO 2006006040	B1	20061102		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

IN 2004CH00637	A	20060526	IN 2004-CH637	20040705 <--
PRIORITY APPLN. INFO.:			IN 2004-CH637	A 20040705 <--

OTHER SOURCE(S): MARPAT 144:128794
ED Entered STN: 20 Jan 2006
GI



I



II

AB The present invention relates to an improved process for the preparation of cephalosporin antibiotics via the formation of intermediate diamine salts of the general form Cp.nM [Cp = cephalosporin antibiotic, such as Cefdinir, Cefoxitin, Cefonicid, etc.; M = ethylenediamine derivative, such as N,N'-diisobutyl-, N,N'-dicyclohexyl-, N,N'-diisopentyl-, N,N'-di(p-anisyl)-, N,N'-dicyclopentyl-, N,N'-di(p-tolyl)-1,2- ethanediamine; n = 0.5 - 2]. Thus, the N,N'-diisobutyl-1,2-ethanediamine salt of Cefonicid (I) was prepd via a reaction of 7β-aminocephem II with O-formyl-D-mandeloyl chloride, adjustment of the reaction mixture to pH 5±1, and finally, addition of the diacetate salt of Me2CHCH2NH(CH2)2NHCH2CHMe2.

L13 ANSWER 18 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1329628 CAPLUS Full-text
DOCUMENT NUMBER: 144:51373

TITLE: Process for the preparation of Cefdinir
INVENTOR(S): Kumar, Raaj
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121154	A1	20051222	WO 2005-US20141	20050608 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-578203P P 20040608 <--
OTHER SOURCE(S): CASREACT 144:51373; MARPAT 144:51373
ED Entered STN: 22 Dec 2005
GI



I

AB Provided are intermediates for use in synthesis of Cefdinir (I) and processes for preparing Cefdinir with such intermediates. Thus, I was prepared with 95% purity via an amidation reaction of 7-amino-3-vinyl-3-cephem-4- carboxylic acid with (Z)-2-(2-amino-4-thiazolyl)-2-acetyloxyiminoacetate in THF/H2O using Et3N.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1178074 CAPLUS Full-text
DOCUMENT NUMBER: 143:440150
TITLE: Preparation of a stable bioavailable crystalline form of cefdinir as an antimicrobial pharmaceutical
INVENTOR(S): Singh, Girij Pal; Sen, Himadri; Srivastava, Dhananjai; Godbole, Himanshu Madhav; Singh, Gurvinder Pal; Mahajan, Pravin Raghunath; Rananaware, Umesh Babanrao;

Nehate, Sagar Purushottam; Wagh, Sanjay Chhagan
PATENT ASSIGNEE(S): Lupin Ltd, India
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2005245738	A1	20051103	US 2004-838431		20040503	<--
US 2006149056	A1	20060706	US 2006-365915		20060302	<--
PRIORITY APPLN. INFO.:			US 2004-838431	A3	20040503	<--

OTHER SOURCE(S): CASREACT 143:440150; MARPAT 143:440150
ED Entered STN: 06 Nov 2005
GI



II

AB The present invention relates to a stable and bioavailable crystalline form of a third generation cephalosporin antibiotic, cefdinir (I) and a process for the preparation thereof. Thus, I can be prepared by reacting Et (Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetate with trityl chloride to get the tritylated amino compound which was hydrolyzed to the sodium salt. The latter compound condensed with cephemcarboxylate II giving protected cefdinir; after deprotection the desired compound was obtained. The present invention also relates to a pharmaceutical composition containing the novel crystalline cefdinir, useful in the treatment of maladies such as bacterial infections.

L13 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1154562 CAPLUS Full-text
DOCUMENT NUMBER: 143:427351
TITLE: Preparation of stable amorphous cefdinir
INVENTOR(S): Server, Nancy E.; Law, Devalina
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2005100368	A2	20051027	WO 2005-US12439	20050411	<--
WO 2005100368	A3	20060824			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006069079	A1	20060330	US 2004-821695	20040927 <--
CA 2562083	A1	20051027	CA 2005-2562083	20050411 <--
EP 1749013	A2	20070207	EP 2005-735632	20050411 <--

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

PRIORITY APPLN. INFO.:	US 2004-821695	A	20040927 <--
	WO 2005-US12439	W	20050411 <--

ED Entered STN: 28 Oct 2005

AB The present invention relates to stable amorphous cefdinir (syn isomer), methods for its preparation, and pharmaceutical compns. comprising the stable amorphous form. Amorphous cefdinir was characterized with Eudragit EPO.

L13 ANSWER 21 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:1154561 CAPLUS Full-text
DOCUMENT NUMBER:	143:422199
TITLE:	Intermediates useful in the synthesis of 3-(2-substituted-vinyl)cephalosporins
INVENTOR(S):	Kumar, Yatendra; Prasad, Mohan; Singh, Kaptan; Prasad, Ashok; Richhariya, Santosh
PATENT ASSIGNEE(S):	Ranbaxy Laboratories Limited, India
SOURCE:	PCT Int. Appl., 33 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100367	A1	20051027	WO 2005-IB978	20050413 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	IN 2004-DE708	A	20040413 <--

OTHER SOURCE(S): CASREACT 143:422199; MARPAT 143:422199

ED Entered STN: 28 Oct 2005

GI



I



II

AB This invention relates to the preparation of crystalline ylide intermediates, such as I [R = H, esterifying residue, metal cation; R1, R2 = H, amine protecting group; R1R2 = divalent amine protecting group], which are useful in the synthesis of 3-(2-substituted-vinyl)cephalosporins. Thus, 7-phenylacetamido-3-(chloromethyl)-3-cephem-4-carboxylic acid diphenylmethyl ester was reacted with PPh3 using NaBr in DMF and CH2Cl2 to form phosphoranylidene ylide I (R = CHPh2, R1 = H, R2 = COCH2Ph) as a crystalline solid. The phosphoranylidene ylide thus formed was then used as an intermediate in the synthesis of the cephalosporin antibiotic, cefditoren sodium (II).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1050932 CAPLUS Full-text
DOCUMENT NUMBER: 143:332490
TITLE: Novel polymorph of cefdinir
INVENTOR(S): Chandrasekaran, Ramasubbu; Senthilkumar, Krishnan; Murugan, Saravan; Sangaraju, Venkatasubba Raju Sivaiah; Reddy, Gaddam Om
PATENT ASSIGNEE(S): Orchid Chemicals & Pharmaceuticals Ltd., India
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005215781	A1	20050929	US 2005-79180		20050315 <--
PRIORITY APPLN. INFO.:			US 2004-553552P	P	20040317 <--

ED Entered STN: 30 Sep 2005
GI



I

AB The present invention relates to novel polymorph (crystal form D) of cefdinir (I). Crystal form D of I was prepared from the N,N'-dicyclohexylethane-1,2-diamine salt of I.

L13 ANSWER 23 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1042254 CAPLUS Full-text
DOCUMENT NUMBER: 143:332671
TITLE: Novel polymorph of cefdinir with improved stability
INVENTOR(S): Chandrasekaran, Ramasubbu; Senthilkumar, Krishnan; Murugan, Saravanan; Sangaraju, Venkatasubba Raju Sivaiah; Reddy, Gaddam Om
PATENT ASSIGNEE(S): Orchid Chemicals & Pharmaceuticals Limited, India
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090360	A1	20050929	WO 2005-IB652	20050315 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2004CH00247	A	20060113	IN 2004-CH247	20040319 <--
PRIORITY APPLN. INFO.:			IN 2004-CH247 A	20040319 <--

ED Entered STN: 29 Sep 2005
AB A method is presented for preparation of a novel polymorph of cefdinir, i.e., the crystalline Form D, by adjusting the pH of a solution of cefdinir salt in mixture of water and organic solvent to 2.5 to 2.7 at low temperature to get cefdinir with new crystal lattice which has better stability. For example, N,N'-dicyclohexylethane-1,2-diamine salt of cefdinir (cefdinir DDA salt) was prepared by adding to 7-amino-3-vinyl-3-cephem-4-carboxylic acid (100 g) in a mixture of THF and water triethylamine (90.0 g) at 20°, followed by 2-mercaptobenzothiazolyl (Z)-(2-aminothiazol-4-yl)-2- (trityloxyimino)acetate (260 g) at 32°, and addition of a solution of N,N'-dicyclohexylethane-1,2-diamine (80 g) in isopropanol to yield 220 g of cefdinir DDA salt (purity

98.27%, water content 1.0%). Cefdinir DDA salt (125 g) was stirred in a mixture of water (3750 mL) and acetone (250 mL) at 35 to 38° and aqueous HCl acid was added to adjust pH to 1.2 to 1.8. After stirring for 5 to 10 min, pH was adjusted to 6.0 using ammonia solution (100 mL). Then carbon was added and stirred at 35 to 38° for 30 min. The filtrate was cooled to 15° and pH was adjusted to 1.5 using aqueous HCl acid to get a clear solution. Then pH was readjusted to 2.5 using ammonia solution at 10 to 15°. The white slurry was stirred for 3 h, the precipitate was filtered, washed with water and air dried to get 66.5 g of cefdinir Form D (purity 98 to 99%, water content 15.07%).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 24 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:626961 CAPLUS Full-text
DOCUMENT NUMBER: 143:115388
TITLE: Process for the preparation of cefdinir Na
INVENTOR(S): Wang, Dengzhi; Hou, Peng
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 4 pp.
CODEN: CNXXEV
DOCUMENT TYPE: **Patent**
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1415615	A	20030507	CN 2002-146335	20021024 <--

PRIORITY APPLN. INFO.: CN 2002-146335 20021024 <--
OTHER SOURCE(S): CASREACT 143:115388
ED Entered STN: 20 Jul 2005
AB Cefdinir Na is prepared by reaction of cefdinir with NaHCO3 at a molar ratio of 1:1, precipitation with ethanol, and vacuum drying at low temperature

L13 ANSWER 25 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:547252 CAPLUS Full-text
DOCUMENT NUMBER: 143:65485
TITLE: Cefdinir crystal B as novel crystalline form and method for preparation
INVENTOR(S): Dandala, Ramesh; Sivakumaran, Meenakshisunderam
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 634,978.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005137182	A1	20050623	US 2004-976230	20041029 <--
US 2004242556	A1	20041202	US 2004-634978	20040224 <--

PRIORITY APPLN. INFO.: IN 2003-MA440 A 20030602 <--
US 2004-634978 A2 20040224 <--
ED Entered STN: 24 Jun 2005
AB The present invention relates to novel crystalline form of Cefdinir, 7β-[(Z)-2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3- cephem-4-

carboxylic acid, herein referred as cefdinir crystal B, processes for preparing cefdinir crystal B, and the incorporation of cefdinir crystal B in pharmaceutical compns. A process for preparing crystalline cefdinir crystal B comprises the steps of: reacting crystals A of cefdinir in water with trifluoroacetic acid at about 35-40°C to form cefdinir trifluoroacetic acid salt; optionally isolating the cefdinir trifluoroacetic acid salt; neutralizing the cefdinir trifluoroacetic acid salt by treatment with a base in water at a temperature between about 0- to 30°C; and isolating cefdinir crystal B by filtration.

L13 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:450931 CAPLUS Full-text
DOCUMENT NUMBER: 142:487516
TITLE: Cefdinir pyridine salt
INVENTOR(S): Duerst, Richard W.; Law, Devalina; Lou, Xiaochun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005113355	A1	20050526	US 2004-939908		20040913 <--
PRIORITY APPLN. INFO.:			US 2003-502441P	P	20030912 <--

ED Entered STN: 27 May 2005
AB The present invention relates to a novel pyridine salt of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4- carboxylic acid (syn isomer), methods for its preparation, and pharmaceutical compns. comprising the salt.

L13 ANSWER 27 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:238740 CAPLUS Full-text
DOCUMENT NUMBER: 142:298138
TITLE: A preparation of cefdinir pyridine salt, useful for the treatment of bacterial infections
INVENTOR(S): Duerst, Richard W.; Law, Devalina; Lou, Xiaochun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 661,148.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005059819	A1	20050317	US 2004-778851		20040213 <--
US 2005059818	A1	20050317	US 2003-661148		20030912 <--
PRIORITY APPLN. INFO.:			US 2003-661148	A2	20030912 <--

ED Entered STN: 18 Mar 2005
AB The invention relates to a preparation of novel pyridine salt of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4- carboxylic acid (cefdinir), useful for the treatment of bacterial infections (no biol. data). The solubility of cefdinir in pyridine was estimated A suspension of

cefdinir in pyridine was allowed to stand at room temperature After 1 wk, the solid from the suspension was separated and the powder X-ray diffraction pattern, 1H NMR, TGA, and IR spectrum of the moist solid were generated.

L13 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1037109 CAPLUS Full-text
DOCUMENT NUMBER: 142:28168
TITLE: Crystalline form of cefdinir
INVENTOR(S): Kumar, Yatendra; Prasad, Mohan; Prasad, Ashok
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004104010	A1	20041202	WO 2004-IB1629	20040520 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2003-DE711 A 20030520 <--
ED Entered STN: 03 Dec 2004
AB The invention relates to a new crystalline form of cefdinir. More particularly, it relates to the preparation of new crystalline form of cefdinir, referred to as 'Form R' and pharmaceutical compns. that include the 'Form R'. It also relates to a method of treatment of infectious diseases comprising administration of the 'Form R'. The Form R was obtained from crystalline cefdinir K salt.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 29 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1036707 CAPLUS Full-text
DOCUMENT NUMBER: 142:23139
TITLE: Process for preparing Cefdinir
INVENTOR(S): Dandala, Ramesh; Korrapati, V. V. Prasada Rao; Sivakumaran, Meenakhshisunderam
PATENT ASSIGNEE(S): Aurobind - Pharma Ltd., India
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242557	A1	20041202	US 2003-676914	20031001 <--

US 7105659 B2 20060912
PRIORITY APPLN. INFO.: IN 2003-MA441 A 20030602 <--
OTHER SOURCE(S): CASREACT 142:23139
ED Entered STN: 03 Dec 2004
GI



I



II



III

AB A process was disclosed for the preparation of the intermediate thioester, 2-mercapto-benzothiazolyl (Z)-2-(2-amino-4-thiazolyl)-2- acetyloxyiminoacetate (I), and its subsequent amidation reaction with 7-amino-3-vinyl-3-cephem-4-carboxylic acid II (R = H) or a corresponding cephem ester, such as II (R = C6H4-4-OMe, C6H4-4-NO2, CHPh2), to form the β-lactam antibiotic Cefdinir (III).
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1036706 CAPLUS Full-text
DOCUMENT NUMBER: 142:28157
TITLE: Novel crystalline form of cefdinir
INVENTOR(S): Dandala, Ramesh; Sivakumaran, Meenakshisunderam
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242556	A1	20041202	US 2004-634978	20040224 <--
US 2005137182	A1	20050623	US 2004-976230	20041029 <--

PRIORITY APPLN. INFO.: IN 2003-MA440 A 20030602 <--
US 2004-634978 A2 20040224 <--
ED Entered STN: 03 Dec 2004
AB The present invention relates to novel crystalline form of cefdinir (cefdinir Crystal B; water content of 5.5 to 7.0% by weight), process to prepare it and the use of cefdinir Crystal B in pharmaceutical compns. A process for preparing crystalline cefdinir Crystal B comprises the steps of (i) reacting cefdinir Crystal A in water with trifluoroacetic acid at 35 to 40° to form cefdinir trifluoroacetic acid salt (CTFA salt), (ii) optionally isolating the CTFA salt, and (iii) neutralizing the CTFA salt by treatment with a base in

water at a temperature between 0° and 30°, isolating cefdinir Crystal B by filtration. A pharmaceutical composition comprises a therapeutically effective amount of cefdinir Crystal B and a pharmaceutically acceptable carrier.

L13 ANSWER 31 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:817895 CAPLUS Full-text
DOCUMENT NUMBER: 141:320013
TITLE: Novel crystal of 7-[2-(2-aminothiazole-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof
INVENTOR(S): Imai, Eiji; Niwa, Hiroyuki
PATENT ASSIGNEE(S): Shiono Chemical Co. Ltd., Japan
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085443	A1	20041007	WO 2004-JP3622	20040318 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224045	A1	20041007	AU 2004-224045	20040318 <--
CA 2520083	A1	20041007	CA 2004-2520083	20040318 <--
EP 1609793	A1	20051228	EP 2004-721656	20040318 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1774441	A	20060517	CN 2004-80010386	20040318 <--

PRIORITY APPLN. INFO.: JP 2003-81273 A 20030324 <--
WO 2004-JP3622 W 20040318 <--
OTHER SOURCE(S): CASREACT 141:320013
ED Entered STN: 07 Oct 2004
AB Disclosed is a novel crystal (B-type crystal) of 7-[2-(2-aminothiazole-4- yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (a syn isomer), characterized in that it exhibits peaks at diffraction angles shown in the following Table 1, in its powder X ray diffraction pattern; Table 1 Diffraction Angle 2θ (°) approx. 11.7 approx. 16.1 approx. 18.6 approx. 21.2 approx. 22.3 approx. 24.4 approx. 26.2 and a method for preparing the novel crystal which comprises forming a crystal from a solution at a temperature of -5 to 5°C in an acidic state. The crystal is not bulky, exhibits good stability and good filterability, and is excellent in the solubility toward water, and thus can be prepared with ease.
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 32 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:565196 CAPLUS Full-text

DOCUMENT NUMBER: 141:123514
TITLE: Préparation of cephalosporins and their intermediates
INVENTOR(S): Datta, Debashish; Dantu, Muralikrishna; Mishra, Brijkishore; Sharma, Pollepeddi Lakshmi Narayana
PATENT ASSIGNEE(S): Lupin Limited, India
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058695	A1	20040715	WO 2002-IN245	20021226 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002368505	A1	20040722	AU 2002-368505	20021226 <--
EP 1575913	A1	20050921	EP 2002-808316	20021226 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2006135761	A1	20060622	US 2005-540770	20051202 <--
PRIORITY APPLN. INFO.:			WO 2002-IN245 A	20021226 <--

OTHER SOURCE(S): CASREACT 141:123514; MARPAT 141:123514
ED Entered STN: 15 Jul 2004
GI



II

AB Novel 4-halo-2-oxyimino-3-oxo-butyric acid-N,N-dimethyl formiminium chloride chlorosulfate derivs., such as XCH2COC(:NOR)COSO2OCH:NMe2Cl I [X = Cl, Br; R = H, alkyl, an easily removable hydroxyl protective group, CH2COOR5, C(CH3)2COOR5, wherein R5 = H, an easily hydrolyzable ester group], were prepared as intermediates for their use in the preparation of cephalosporin antibiotics, such II [R1 = R; R1 = H, OMe; R2 = H; R3 = H, a neg. charge or together with the CO2- group to which R3 is attached = ester, alkali, alkaline earth metal; R4 = H, substituent useful in cephalosporin chemical]. The process of preparing I involves reacting 4-halo-2-oxyimino-3-oxobutyric acid with N,N-dimethylformiminium chloride chlorosulfate, in an organic solvent at

a temperature ranging from -30 °C to -15 °C. Thus, reaction between I and 7-aminocephalosporanic acid in CH2Cl2 containing hexamethyldisilazane, gives 7-[4-bromo-2(Z)-methoxyimino- 3-oxobutyramido]-cephalosporanic acid, which was reacted with thiourea to afford cefotaxim. The cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, cefquinome, ceftazidime, cefteram pivoxil, ceftiofur, ceftizoxime, ceftriaxone and cefuzonam.

L13 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:546513 CAPLUS Full-text
DOCUMENT NUMBER: 141:88964
TITLE: Process for preparing crystalline cefdinir salts
INVENTOR(S): Pozzi, Giovanni; Martin Gomez, Patricio; Alpegiani, Marco; Cabri, Walter
PATENT ASSIGNEE(S): Antibioticos S.p.A., Italy
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056835	A1	20040708	WO 2003-EP13524	20031201 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003293746	A1	20040714	AU 2003-293746	20031201 <--
EP 1572699	A1	20050914	EP 2003-789109	20031201 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006511561	T	20060406	JP 2004-561199	20031201 <--
US 2006074236	A1	20060406	US 2005-539122	20050616 <--
US 7173126	B2	20070206		

PRIORITY APPLN. INFO.: IT 2002-MI2724 A 20021220 <--
WO 2003-EP13524 W 20031201 <--

OTHER SOURCE(S): MARPAT 141:88964
ED Entered STN: 08 Jul 2004
GI



I

AB Cefdinir salts, such as I.nH3PO4 [R1, R2 = H; n = 1 - 3 (II)], the hydrates and solvates thereof, were prepared from cefdinir intermediates, I (R1 = benzhydryl, trityl, p-methoxybenzyl; R2 = benzhydryl, tert-Bu, p-methoxybenzyl), or crude cefdinir I (R1, R2 = H) by the treatment with phosphoric acid. Thus, I (R1 = CPh3, R2 = H) was dissolved in 85% phosphoric acid and acetonitrile, and reaction mixture was heated at 45°C for 2 h, to afford cefdinir phosphate. The use of II for the preparation and purification of cefdinir is also disclosed.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 34 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:453223 CAPLUS Full-text
DOCUMENT NUMBER: 141:6966
TITLE: Process for preparing cefdinir and its amorphous hydrate
INVENTOR(S): Deshpande, Pandurang Balwant; Khadangale, Bhausaheb Pandharinath; Ramasubbu, Chandrasekaran
PATENT ASSIGNEE(S): Orchid Chemicals & Pharmaceuticals Ltd., India
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004046154	A1	20040603	WO 2003-IB5032		20031110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003276525	A1	20040615	AU 2003-276525		20031110 <--
US 2006094703	A1	20060504	US 2005-532753		20050513 <--
PRIORITY APPLN. INFO.:			IN 2002-MA848	A	20021115 <--
			IN 2003-MA152	A	20030226 <--
			WO 2003-IB5032	W	20031110 <--

OTHER SOURCE(S): CASREACT 141:6966; MARPAT 141:6966
ED Entered STN: 04 Jun 2004
GI



I



III

AB The present invention discloses a process for preparing cefdinir [I; R1 = H; R2 = CO2H (II)] and its monohydrate via condensing 7-amino-3-cephem-4-carboxylic acid with III (X = ester, thioester, halo, etc.) in the presence of a tertiary amine and an organic solvent, followed by treatment with a base to produce I [R1 = C(Ph)3; R2 = carboxylate ion (IV)], and hydrolyzing IV, using an acid in the presence of a solvent, to produce II. Thus, reaction between III (X = OH) and 2-mercapto-5-phenyl-1,3,4- oxadiazole yielded 2-mercapto-5-phenyl-1,3,4-oxadiazolyl-(Z)-(2- aminothiazol-4-yl)-2-(trityloxyimino) acetate, which, on condensation with 7-amino-3-vinyl-3-cephem-4-carboxylic acid and subsequent hydrolysis, afforded II.

L13 ANSWER 35 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:355098 CAPLUS Full-text
DOCUMENT NUMBER: 140:375021
TITLE: Intermediate cefdinir salts
INVENTOR(S): Pozzi, Giovanni; Martin Gomez, Patricio; Alpegiani, Marco; Cabri, Walter
PATENT ASSIGNEE(S): Antibioticos S.P.A., Italy
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035800	A2	20040429	WO 2003-EP10718	20030926 <--
WO 2004035800	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500791	A1	20040429	CA 2003-2500791	20030926 <--
AU 2003293585	A1	20040504	AU 2003-293585	20030926 <--
EP 1546155	A2	20050629	EP 2003-788921	20030926 <--
EP 1546155	B1	20060705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501305	T	20060112	JP 2004-544046	20030926 <--
AT 332304	T	20060715	AT 2003-788921	20030926 <--
US 2006111566	A1	20060525	US 2005-529649	20051011 <--
PRIORITY APPLN. INFO.:			IT 2002-MI2076 A	20021001 <--
			WO 2003-EP10718 W	20030926 <--

OTHER SOURCE(S): MARPAT 140:375021
ED Entered STN: 30 Apr 2004
GI



x B

I



II

AB Disclosed are salts of the general formula (I) wherein R1 is H or an amino-protecting group, R2 is and OH-protecting group, and B is NH3 or an organic base, and a process for the preparation thereof. These salts are useful intermediates for the preparation of cefdinir (II).

L13 ANSWER 36 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:162698 CAPLUS Full-text
DOCUMENT NUMBER: 140:217437
TITLE: Process for the preparation of cefdinir intermediate
INVENTOR(S): Kremminger, Peter; Wolf, Siegfried; Ludescher, Johannes
PATENT ASSIGNEE(S): Sandoz G.m.b.H., Austria
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016623	A1	20040226	WO 2003-EP8944	20030812 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003255424	A1	20040303	AU 2003-255424	20030812 <--
EP 1554289	A1	20050720	EP 2003-787771	20030812 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500356	T	20060105	JP 2004-528469	20030812 <--
US 2006025586	A1	20060202	US 2005-524397	20050211 <--
PRIORITY APPLN. INFO.:			AT 2002-1223 A	20020813 <--

AT 2002-1588 A 20021018 <--
WO 2003-EP8944 W 20030812 <--

OTHER SOURCE(S): MARPAT 140:217437
ED Entered STN: 29 Feb 2004
GI



I

AB A process is claimed for the synthesis of 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid (I), in the form of a crystalline salt, such as I.HX [X = Cl-, HSO4-,RYO3-, H2NSO3-, 1/2(SO4)2-; R = alkyl, aryl; Y = S, P], and their use in the preparation of pure cefdinir. Thus, a reactive derivative of syn-2-(2-aminothiazol-4-yl)2-(methylcarbonyloxyimino)-acetic acid, e.g., syn-2-(2-aminothiazol-4-yl)2-(methylcarbonyloxyimino)-acetic acid mercapto-benzothiazolyl ester is reacted with 7-amino-3-vinyl-3-cephem-4-carboxylic acid in silylated form to obtain I, in which the carboxylic acid is optionally silylated. In another aspect, the present invention relates to salt of I, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 37 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:472518 CAPLUS Full-text
DOCUMENT NUMBER: 139:41841
TITLE: Preparation of crystalline cefdinir potassium dihydrate
INVENTOR(S): Kumar, Yatendra; Prasad, Mohan; Prasad, Ashok; Singh, Shailendra Kumar; Kumar, Neela Praveen
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050124	A1	20030619	WO 2002-IB5315	20021212 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003091261 A1 20031106 WO 2002-IB1410 20020426 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002307805 A1 20031110 AU 2002-307805 20020426 <--
BR 2002015709 A 20050329 BR 2002-15709 20020426 <--
CN 1628118 A 20050615 CN 2002-829048 20020426 <--
EP 1546154 A1 20050629 EP 2002-807297 20020426 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2005530741 T 20051013 JP 2003-587819 20020426 <--
AU 2002347539 A1 20030623 AU 2002-347539 20021212 <--
EP 1458728 A1 20040922 EP 2002-783470 20021212 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
US 2005080255 A1 20050414 US 2004-498406 20021212 <--
CN 1617875 A 20050518 CN 2002-828008 20021212 <--
JP 2005516011 T 20050602 JP 2003-551148 20021212 <--
US 2006040915 A1 20060223 US 2005-513004 20050714 <--
PRIORITY APPLN. INFO.: IN 2001-DE1242 A 20011213 <--
WO 2002-IB1410 A 20020426 <--
WO 2002-IB5315 W 20021212 <--

ED Entered STN: 20 Jun 2003
AB The present invention relates to a novel crystalline cefdinir potassium dihydrate (I), to a process for its preparation and to a method of preparing pure cefdinir via the crystalline salt. Thus, cefdinir was suspended in water and acetone and potassium acetate was added to the suspension to form the I.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:408080 CAPLUS Full-text
DOCUMENT NUMBER: 140:42117
TITLE: An alternative procedure for preparation of cefdinir
AUTHOR(S): Gonzalez, Maritza; Rodriguez, Zalua; Tolon, Blanca; Rodriguez, Juan C.; Velez, Herman; Valdes, Barbara; Lopez, Miguel A.; Fini, Adamo
CORPORATE SOURCE: Department of Chemical Synthesis, Center of Pharmaceutical Chemistry, Atabey, Ciudad de la Habana, Playa, 200, Cuba
SOURCE: Farmaco (2003), 58(6), 409-418
CODEN: FRMCE8; ISSN: 0014-827X
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:42117
ED Entered STN: 29 May 2003
AB Cefdinir, a broad spectrum third-generation cephalosporin for oral administration, was prepared by the following synthetic pathway: synthesis of diphenylmethyl 7β-amino-3-vinyl-3-cephem-4-carboxylate hydrochloride from 7-aminocephalosporanic acid (7-ACA), preparation of sodium 2-(2-

tritylaminothiazol-4-yl)-(Z)-2-(tritylhydroxyimino) acetate from Et acetoacetate, coupling of both intermediaries to obtain diphenylmethyl 7β-[2-(2-tritylaminothiazol-4-yl)-(Z)-2-tritylhydroxyimino]-3-vinyl-3- cephem-4-carboxylate and final cleavage of trityl and diphenylmethyl protective groups. This procedure allows to obtain better yields of cefdinir and to avoid the use of diketene during the synthesis of this antibiotic by the previously reported method.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 39 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:334829 CAPLUS Full-text
DOCUMENT NUMBER: 138:343889
TITLE: Novel pharmaceutical compounds containing drugs bound to polypeptides
INVENTOR(S): Picariello, Thomas
PATENT ASSIGNEE(S): New River Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 4662 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003034980	A2	20030501	WO 2001-US43089	20011114 <--
WO 2003034980	A8	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2428971	A1	20030501	CA 2001-2428971	20011114 <--
EP 1401374	A1	20040331	EP 2001-274606	20011114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2006516948	T	20060713	JP 2003-537549	20011114 <--
US 2004063628	A1	20040401	US 2002-156527	20020529 <--
US 7060708	B2	20060613		
IN 2003KN00775	A	20050204	IN 2003-KN775	20030613 <--
PRIORITY APPLN. INFO.:			US 2000-274622P	P 20001114
			US 1999-265415	B2 19990310
			US 1999-411238	B2 19991004
			WO 2000-US5693	A 20000306
			US 2000-642820	A2 20000822
			US 2000-247561P	P 20001114
			US 2000-247622P	P 20001114
			US 2000-248620P	P 20001116
			US 2000-248658P	P 20001116
			US 2000-248659P	P 20001116
			US 2000-248660P	P 20001116
			US 2000-248662P	P 20001116
			US 2000-248663P	P 20001116
			US 2000-248685P	P 20001116

US	2000-248737P	P	20001116
US	2000-248738P	P	20001116
US	2000-248764P	P	20001116
US	2000-248767P	P	20001116
US	2000-248768P	P	20001116
US	2000-248769P	P	20001116
US	2000-248770P	P	20001116
US	2000-248771P	P	20001116
US	2000-248772P	P	20001116
US	2000-248774P	P	20001116
US	2000-248776P	P	20001116
US	2000-248777P	P	20001116
US	2000-248778P	P	20001116
US	2000-248779P	P	20001116
US	2000-248782P	P	20001116
US	2000-248787P	P	20001116
US	2000-248794P	P	20001116
US	2000-248795P	P	20001116
US	2000-248796P	P	20001116
US	2000-248797P	P	20001116
US	2001-933708	A2	20010822 <--
US	2001-986426	A2	20011108 <--
US	2001-987458	B2	20011114 <--
WO	2001-US43089	W	20011114 <--
US	2001-988034	B2	20011116 <--
US	2001-988071	B2	20011116 <--
WO	2001-US43115	B2	20011116 <--
WO	2001-US43117	B2	20011116 <--
US	2002-358381P	P	20020222 <--
US	2002-366258P	P	20020322 <--

ED Entered STN: 02 May 2003

AB Compns. comprising polypeptides and drugs covalently attached to the polypeptide are disclosed. Also provided is a method for delivery of these drugs to a patient comprising administering to the patient a composition comprising a polypeptide and a drug covalently attached to the polypeptide. Also provided is a method for protecting drugs from degradation comprising covalently attaching them to a polypeptide. Also provided is a method for controlling release of drugs from a composition comprising covalently attaching them to the polypeptide.

L13 ANSWER 40 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:228449 CAPLUS Full-text
DOCUMENT NUMBER: 139:169449
TITLE: Determination of cefdinir and its related substances by HPLC
AUTHOR(S): Wang, Xing-lin
CORPORATE SOURCE: Tianjin Institute of Pharmaceutical Research, Tianjin, 300193, Peop. Rep. China
SOURCE: Zhongguo Xinyao Zazhi (2003), 12(2), 114-117
CODEN: ZXZHA6; ISSN: 1003-3734
PUBLISHER: Zhongguo Xinyao Zazhishe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

ED Entered STN: 25 Mar 2003

AB A HPLC method for the determination of cefdinir and its related substances was established. A C18 column (250 mm + 4.6mm, 5μm) was used. The mobile phase was the mixture of 0.025 mol·L-1 di-ammonium hydrogen phosphate adjusted to pH 5.0 with phosphoric acid and acetonitrile (89:11). The UV detection wavelength was 225 nm. The method was proved to be selective for separation

of cefdinir, its byproducts, degradation products and E-isomer. The method is simple and selective, and suitable for the determination of cefdinir and its impurities.

L13 ANSWER 41 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:946292 CAPLUS Full-text
DOCUMENT NUMBER: 138:13981
TITLE: Process for the preparation of high purity cefdinir via formations of crystalline acid salts
INVENTOR(S): Lee, Gwan Sun; Chang, Young Kil; Kim, Hong Sun; Park, Chul Huyn; Park, Gha Seung; Kim, Cheol Kyung
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098884	A1	20021212	WO 2002-KR1064	20020605 <--
W: CN, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
KR 2002092612	A	20021212	KR 2001-31339	20010605 <--
EP 1392703	A1	20040303	EP 2002-730990	20020605 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
CN 1512996	A	20040714	CN 2002-811334	20020605 <--
JP 2004534053	T	20041111	JP 2003-502005	20020605 <--
US 2004210049	A1	20041021	US 2003-479291	20031125 <--
US 7157576	B2	20070102		

PRIORITY APPLN. INFO.: KR 2001-31339 A 20010605 <--
WO 2002-KR1064 W 20020605 <--

ED Entered STN: 13 Dec 2002
GI



I

AB High purity cefdinir is prepared in a high yield by a process comprising the steps of: treating a cefdinir intermediate with a formic acid-sulfuric acid mixture or a formic acid-methanesulfonic acid mixture to obtain a crystalline salt of cefdinir I [HX = H2SO4, MeSO3H] and reacting the crystalline salt with a base in a solvent. Thus, crystalline cefdinir.TsOH.2DMAC was prepared by an amidation reaction of (Z)-2-amino-α-[(triphenylmethoxy)imino]-4-

thiazoleethanethioic acid S-2-benzothiazolyl ester with 7-amino-3-vinyl-3-cephem-4-carboxylic acid using Bu3N in N,N-dimethylacetamide (DMAC), followed by treatment with TsOH. Crystalline cefdinir.TsOH.2DMAC was converted to crystalline cefdinir.H2SO4 in 91% yield using 90% HCO2H, 98% H2SO4 and MeCN. 99.9% Pure cefdinir was then obtained by suspending crystalline cefdinir.H2SO4 in H2O and adjusting the pH to 3.4 to 3.6 using Na2CO3. Also, 99.8% pure cefdinir was prepared via a similar sequence in which the intermediate salt was cefdinir.MeSO3H.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 42 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:449666 CAPLUS Full-text
DOCUMENT NUMBER: 137:20252
TITLE: Process for producing anhydrous aminothiazole derivatives by dehydration in ketone or acetonitrile solvent
INVENTOR(S): Ono, Hiroki; Hayashi, Masaru; Ohnishi, Masaru; Ohkawa, Kazuo; Kitayama, Masato
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046175	A1	20020613	WO 2001-JP10356	20011128 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430840	A1	20020613	CA 2001-2430840	20011128 <--
AU 2002022553	A5	20020618	AU 2002-22553	20011128 <--
EP 1340751	A1	20030903	EP 2001-999567	20011128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004034233	A1	20040219	US 2003-432605	20030603 <--
US 6878827	B2	20050412		

PRIORITY APPLN. INFO.: JP 2000-368319 A 20001204
WO 2001-JP10356 W 20011128 <--
OTHER SOURCE(S): MARPAT 137:20252
ED Entered STN: 14 Jun 2002
GI



I

AB Disclosed is a novel process for industrially producing an anhydrous 2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetic acid (I; R1 = acyl, protected carboxy-lower alkyl, alkyl) which is characterized in that I hydrate is treated in ketone solvent or MeCN. Anhydrous I is reacted with halogenating agent such as PCl5, converted into acid chloride, and then reacted with 7-aminocephem compound to prepare a broad spectrum antibacterial agent (no data). An amount of halogenating agent required is reduced to .apprx.1 to 1.2 equiv compared to .apprx.3 equiv when I hydrate is used. Thus, 20.0 g syn-2-(2-aminothiazol-4-yl)-2-acetoxyiminoacetic acid (II) dihydrate was suspended in 200 mL acetone with stirring and heated under reflux at 55-56° for 1 h, and cooled at 5°, followed by filtration of precipitated crystals, an washing and vacuum-drying, to give 16.4 g anhydrous crystals of II. II (12.5 g) was suspended in 125 mL CH2Cl2 with stirring, cooled at -20 to -25°, treated with 13.6 g PCl5, and allowed to react at the same temperature, followed by filtration of precipitated crystals, washing with CH2Cl2, and vacuum-drying, to give 14.6 g 2-(2-aminothiazol-4-yl)-2- (acetoxyimino)acetyl chloride hydrochloride (III). 7-Amino-3-vinyl-3- cephem-4-carboxylic acid (4.52 g) and 10.2 g 1,3-bis(trimethylsilyl)urea were suspended in 80 mL EtOAc, heated under reflux for 120 h for silylation, cooled at -20°, followed by adding 6.25 g III, and the resulting mixture was allowed to react for 30 min to give 95% 7-[syn-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-vinyl-3-cephem- 4-carboxylic acid.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 43 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:880903 CAPLUS Full-text
DOCUMENT NUMBER: 137:125013
TITLE: Synthesis of cefdinir
AUTHOR(S): Lin, Gui-chun; Liu, Li; Ma, Ling-tai; Min, Ji-mei; Zhang, Li-he
CORPORATE SOURCE: Natl. Res. Lab. Natural Biomimetic Drugs, Peking Univ., Beijing, 100083, Peop. Rep. China
SOURCE: Hecheng Huaxue (2001), 9(5), 383-385
CODEN: HEHUE2; ISSN: 1005-1511
PUBLISHER: Hecheng Huaxue Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 137:125013
ED Entered STN: 07 Dec 2001

AB Cefdinir was synthesized via the condensation of 2-(2-aminothiazol-4-yl)-2-(Z)-(acetyinmino)acetyl chloride with 7-amino-3-vinyl-3-cephem-4- carboxylic acid. Under the optimization reaction conditions 60% total yield was achieved.

L13 ANSWER 44 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:767504 CAPLUS Full-text
DOCUMENT NUMBER: 135:303724
TITLE: Preparation of 3-vinylcephem compound from protected compounds
INVENTOR(S): Kameyama, Yutaka; Fukae, Kazuhiro
PATENT ASSIGNEE(S): Ohtsuka Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001294590	A	20011023	JP 2000-111448	20000413 <--
WO 2001079211	A1	20011025	WO 2001-JP3182	20010413 <--
W: CN, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1273587	A1	20030108	EP 2001-919924	20010413 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
CN 1134445	B	20040114	CN 2001-800920	20010413 <--
HK 1048112	A1	20041126	HK 2003-100146	20030107 <--

PRIORITY APPLN. INFO.:	JP 2000-111448	A	20000413
	WO 2001-JP3182	W	20010413 <--

OTHER SOURCE(S): CASREACT 135:303724; MARPAT 135:303724
ED Entered STN: 23 Oct 2001
GI



I

AB Cefdinir is prepared by treatment of protected 3-vinylcephem compds. I [R1-R3 = H, (un)substituted arylmethyl; R1 = R2 = R3 ≠ H] with perhalogenic acid and organic protonic acid in organic solvent. Thus, I (R1 = R3 = H, R2 = trityl) was treated with HClO4 and HCO2H at 30° for 1 h in CH2Cl2 to give 95% cefdinir.

L13 ANSWER 45 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:564833 CAPLUS Full-text
DOCUMENT NUMBER: 135:152367
TITLE: Nitrate salts of antimicrobial agents
INVENTOR(S): Del Soldato, Piero; Benedini, Francesca; Antognazza, Patrizia
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054691	A1	20010802	WO 2001-EP430	20010116 <--
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT	2000MI0092	A1	20010726	IT 2000-MI92	20000126 <--
IT	1317735	B1	20030715		
CA	2397754	A1	20010802	CA 2001-2397754	20010116 <--
AU	200137308	A	20010807	AU 2001-37308	20010116 <--
AU	785330	B2	20070118		
BR	2001007824	A	20021105	BR 2001-7824	20010116 <--
EP	1253924	A1	20021106	EP 2001-909631	20010116 <--
EP	1253924	B1	20060419		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP	2003520814	T	20030708	JP 2001-554675	20010116 <--
AT	323488	T	20060515	AT 2001-909631	20010116 <--
PT	1253924	T	20060929	PT 2001-909631	20010116 <--
RU	2288231	C2	20061127	RU 2002-120480	20010116 <--
US	2003105066	A1	20030605	US 2002-181424	20020724 <--
US	6794372	B2	20040921		

PRIORITY APPLN. INFO.:	IT 2000-MI92	A	20000126
	WO 2001-EP430	W	20010116 <--

OTHER SOURCE(S): MARPAT 135:152367

ED Entered STN: 03 Aug 2001

AB Nitrate salts of antiviral, antifungal, and antibacterial agents such as acyclovir, tetracycline, etc. were prepared Growth inhibition of, e.g., an S. Aureus strain by title compds. was demonstrated.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 46 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:708773 CAPLUS Full-text

DOCUMENT NUMBER: 131:327498

TITLE: A method for crystallizing a β-lactam antibiotic

INVENTOR(S): Van Der Does, Thomas; Kuipers, Rienk Hendrik

PATENT ASSIGNEE(S): DSM N.V., Neth.; Van Der Does, Thomas

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO	9955710	A1	19991104	WO 1999-NL246	19990427
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU	9935395	A	19991116	AU 1999-35395	19990427
BR	9910085	A	20001226	BR 1999-10085	19990427
TR	200003131	T2	20010122	TR 2000-200003131	19990427 <--
EP	1075479	A1	20010214	EP 1999-917236	19990427 <--
	R: AT, BE, ES, FR, GB, IT, NL				

PRIORITY APPLN. INFO.:	EP 1998-201398	A	19980429
	WO 1999-NL246	W	19990427

OTHER SOURCE(S): MARPAT 131:327498

ED Entered STN: 05 Nov 1999

AB The invention relates to a method for crystallizing a β-lactam, wherein the β-lactam is crystallized from a nitric acid solution E.g., at 20°, cefaclor monohydrate (11.0 g) was suspended in water (55 mL) and 4M HNO3 (8.1 g) was added to give a pH of 1.0. In order to dissolve all material, water (31 mL) was added while the pH was maintained at 1.0 using 4M HNO3 (2.5 g). Cefaclor monohydrate was crystallized by adding a 25% solution of NH4OH (3.8 mL) until the pH value of 6.2 was reached. The crystals thus produced were isolated by filtration, washed with water and dried under vacuum to give 8.8 g cefaclor monohydrate. The mother liquor (110 g) contained 2.2 g of dissolved cefaclor monohydrate.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 47 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:682396 CAPLUS Full-text
DOCUMENT NUMBER: 129:275784
TITLE: synthesis of crystalline dicyclohexylamine salt of cefdinir
INVENTOR(S): Sturm, Hubert; Wolf, Siegfried; Ludescher, Johannes
PATENT ASSIGNEE(S): Biochemie G.m.b.H., Austria
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845299	A1	19981015	WO 1998-EP1953	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AT 9700570	A	19981115	AT 1997-570	19970404
AT 405283	B	19990625		
CA 2283718	A1	19981015	CA 1998-2283718	19980402
AU 9874288	A	19981030	AU 1998-74288	19980402 <--
AU 731413	B2	20010329		
EP 973779	A1	20000126	EP 1998-921425	19980402 <--
EP 973779	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
TR 9902406	T2	20000221	TR 1999-2406	19980402
BR 9809745	A	20000620	BR 1998-9745	19980402
JP 2000514833	T	20001107	JP 1998-542358	19980402 <--
JP 3421354	B2	20030630		
HU 200002987	A2	20010228	HU 2000-2987	19980402 <--
AT 244249	T	20030715	AT 1998-921425	19980402 <--
NO 9904466	A	19990915	NO 1999-4466	19990915
US 6350869	B1	20020226	US 1999-381947	19990927 <--
MX 9909045	A	20000228	MX 1999-9045	19991001

PRIORITY APPLN. INFO.:			
AT 1997-570	A	19970404	
EP 1998-921425	A	19980402	
WO 1998-EP1953	W	19980402	

ED Entered STN: 28 Oct 1998
AB A process for production of cefdinir in the form of a salt with dicyclohexylamine, and its use in the purification of impure cefdinir is described.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 48 OF 48 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:547291 CAPLUS Full-text
DOCUMENT NUMBER: 127:149040
TITLE: Process for preparation of cefdinir
INVENTOR(S): Lee, Gwan Sun; Chang, Young Kil; Chun, Jong Pil; Koh, Joon Hyung
PATENT ASSIGNEE(S): Hanmi Pharmaceutical Co., Ltd., S. Korea; Lee, Gwan Sun; Chang, Young Kil; Chun, Jong Pil; Koh, Joon Hyung
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724358	A1	19970710	WO 1996-KR250	19961226
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
KR 174432	B1	19990218	KR 1995-58694	19951227
KR 174431	B1	19990218	KR 1995-58695	19951227
EP 874853	A1	19981104	EP 1996-943357	19961226 <--
EP 874853	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000502700	T	20000307	JP 1997-524230	19961226
AT 218572	T	20020615	AT 1996-943357	19961226 <--
PT 874853	T	20020930	PT 1996-943357	19961226 <--
ES 2175167	T3	20021116	ES 1996-943357	19961226 <--
US 6093814	A	20000725	US 1998-68719	19980518

PRIORITY APPLN. INFO.:	KR 1995-58694	A	19951227
	KR 1995-58695	A	19951227
	WO 1996-KR250	W	19961226

OTHER SOURCE(S): CASREACT 127:149040; MARPAT 127:149040
ED Entered STN: 28 Aug 1997
GI



I



II

AB Cefdinir I (R = H), a cephalosporin antibiotic, was prepared in an excellent color and purity and with a good yield. Cefdinir was prepared by N-acylation of 7-amino-3-vinyl-3-cephem-4-carboxylic acid with thio ester II (Z = 2-benzothiazolylthio) and crystallization of the resulting ester with 4-MeC6H4SO3H and Me2NCOMe to form crystals of I (R = CPh3).4-MeC6H4SO3H.2Me2NCOMe, which were then converted to cefdinir with the use of formic acid. Formation of the cefdinir amide linkage was also accomplished starting from phosphoryl ester II [Z = OP(O)(OEt)2].

Search History

```
FILE 'REGISTRY' ENTERED AT 16:27:58 ON 15 FEB 2007
                E CEFDINIR/CN
L1              1 SEA ABB=ON  PLU=ON  CEFDINIR/CN
                D

     FILE 'REGISTRY' ENTERED AT 16:28:46 ON 15 FEB 2007
L2              STR 91832-40-5
L3              2 SEA FAM SAM L2
                D SCAN
L4             45 SEA FAM FUL L2

     FILE 'CAPLUS' ENTERED AT 16:29:34 ON 15 FEB 2007
L5            510 SEA ABB=ON  PLU=ON  L4
L6             62 SEA ABB=ON  PLU=ON  L4/P
L7             62 SEA ABB=ON  PLU=ON  L4(L)PREP+NT/RL
L8             52 SEA ABB=ON  PLU=ON  L7 AND PATENT/DT
L9             44 SEA ABB=ON  PLU=ON  L8 AND (PRY>=2001 OR PY>=2001 OR AY>=2001)

L10             8 SEA ABB=ON  PLU=ON  L8 NOT L9
L11            10 SEA ABB=ON  PLU=ON  L7 NOT L8
L12             4 SEA ABB=ON  PLU=ON  L11 AND PY>=2001
L13            48 SEA ABB=ON  PLU=ON  L9 OR L12
                SAVE TEMP L13 BER906HC1A/A

    FILE 'CAPLUS' ENTERED AT 16:47:43 ON 15 FEB 2007
                D QUE L13
                D IBIB ED ABS 1-48
```